title: Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an Asian perspective.
abstract: BACKGROUND
  Data on quality of life (QOL) after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) is scarce in the Asian population. This study assesses QOL outcomes after CRS and HIPEC in an Asian cancer center.
  
  
  METHODS
  Patients who completed CRS + HIPEC 6-18 months ago (27 patients) were enrolled in the study. QOL was measured via the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaires. The scores were compared with a group of 393 disease-free cancer patients, not on active treatment, who had ECOG scores of either 0 or 1. The 1-sample t test was used to compare differences in QOL scores between the 2 groups.
  
  
  RESULTS
  A total of 27 patients were analyzed, of which 22 (81 %) were females. Median age was 51 years (15-59 years). CRS + HIPEC were performed for ovarian cancer in 15 patients (55 %), appendiceal carcinoma in 5 patients (19 %), and colorectal carcinoma in 4 patients (15 %). The median intraoperative peritoneal carcinomatosis index (PCI) score was 15 (2-31) while the completeness of CC score was 0 and 1 in 25 and 2 patients, respectively. The median duration after CRS + HIPEC was 10 months (6-16 months). Global health status and functional and symptom scores were largely similar between patients after CRS + HIPEC and the control group. Cognitive functioning scores and fatigue scores were significantly better in the group after CRS + HIPEC (p = 0.014 and 0.04).
  
  
  CONCLUSIONS
  QOL after CRS and HIPEC can be equivalent to that of well-functioning, disease-free cancer patients.
authors.affiliation: Department of Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
authors.forename: Winson Jianhong
authors.initials: WJ
authors.lastname: Tan
authors.forename: Joelle Fui Sze
authors.initials: JF
authors.lastname: Wong
authors.forename: Claramae Shulyn
authors.initials: CS
authors.lastname: Chia
authors.forename: Grace Hwee Ching
authors.initials: GH
authors.lastname: Tan
authors.forename: Khee Chee
authors.initials: KC
authors.lastname: Soo
authors.forename: Melissa Ching Ching
authors.initials: MC
authors.lastname: Teo
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001208:Asia; D010478:Chemotherapy, Cancer, Regional Perfusion; D015179:Colorectal Neoplasms / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000628:therapy*; D011379:Prognosis; D011446:Prospective Studies; D011788:Quality of Life; D055815:Young Adult